Breast Cancer and Human Epidermal Growth Factor Receptor 2: Overexpression and Related Drugs

Abstract

As a prognostic and predictive biomarker of some illnesses, overexpression of HER-2 is seen in roughly 15–30% of breast cancers (also known as BC), 10–30% of gastric/gastroesophageal cancers, and many other types of cancers. Since the overexpression of HER-2 occurs in many types of cancers, the relationship between HER-2 and the diseases urgently needs to be illustrated and corresponding drugs and treatment schemes need to be developed. Up to now, several HER-2-targeted drugs are in use and have become an important part of standard treatment options, including but not limited to Trastuzumab, Pertuzumab, Margetuximab, Trastuzumab Emtansine(T-DM1), etc. Given the high mortality rate and connection between HER-2 overexpression and BC, many of these drugs are used in the treatment and prognosis of BC. Here in this article, a review of the latest studies about the relationship between BC and HER-2 and a simple introduction of them were made and what is most important is that some related drugs targeting HER-2 together with their development were also listed.